Sarepta Therapeutics agrees to pay $39 million to settle gene therapy dispute with Regenxbio
read at Endpoints ↗DealNeutral
Sarepta Therapeutics has agreed to resolve a dispute with Regenxbio by paying $39 million.
The payment settles claims related to gene therapy technology that both companies have been developing.
The settlement amount was disclosed in a recent news briefing, with no further details on the underlying allegations.
In the same briefing, Vida Therapeutics announced it is pursuing a fourth funding round, indicating ongoing capital raising activity.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Sarepta to pay Regenxbio $39M to settle gene therapy claims; Vida eyes fourth fund”
read at Endpoints ↗85 words · retrieved 51m ago
comments(0)
5-min edit window · permanent after that